Tumor necrosis factor α decreases glucagon-like peptide-2 expression by up-regulating G-protein-coupled receptor 120 in Crohn disease.

[1]  Karen L Jones,et al.  Glucagon-Like Peptide 1 Attenuates the Acceleration of Gastric Emptying Induced by Hypoglycemia in Healthy Subjects , 2014, Diabetes Care.

[2]  S. L. la Fleur,et al.  Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. , 2014, The Journal of endocrinology.

[3]  D. Burrin,et al.  Bile acids induce glucagon-like peptide 2 secretion with limited effects on intestinal adaptation in early weaned pigs. , 2013, The Journal of nutrition.

[4]  A. M. Habib,et al.  Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells , 2013, Diabetologia.

[5]  S. Koo,et al.  PPAR-γ Activation Increases Insulin Secretion through the Up-regulation of the Free Fatty Acid Receptor GPR40 in Pancreatic β-Cells , 2013, PloS one.

[6]  A. Forbes,et al.  Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. , 2012, Gastroenterology.

[7]  P. Theil,et al.  G protein-coupled receptor120 (GPR120) transcription in intestinal epithelial cells is significantly affected by bacteria belonging to the Bacteroides, Proteobacteria, and Firmicutes phyla. , 2012, Journal of animal science.

[8]  Xiaojie Li,et al.  GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility. , 2012, American journal of physiology. Endocrinology and metabolism.

[9]  M. Deyoung,et al.  GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence , 2012, Diabetes, obesity & metabolism.

[10]  R. Gilroy,et al.  Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome , 2011, Gut.

[11]  Rashmi Chandra,et al.  Characterization of basal pseudopod-like processes in ileal and colonic PYY cells , 2011, Journal of Molecular Histology.

[12]  S. Watkins,et al.  GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects , 2010, Cell.

[13]  A. Buchman,et al.  Teduglutide, a novel mucosally active analog of glucagon‐like peptide‐2 (GLP‐2) for the treatment of moderate to severe Crohn's disease , 2010, Inflammatory bowel diseases.

[14]  H. Hara,et al.  GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate, in rats. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[15]  S. Ishizuka,et al.  alpha-Lactalbumin hydrolysate stimulates glucagon-like peptide-2 secretion and small intestinal growth in suckling rats. , 2009, The Journal of nutrition.

[16]  A. Thomson,et al.  Intestinal hormones and growth factors: effects on the small intestine. , 2009, World journal of gastroenterology.

[17]  H. Han,et al.  Linoleic acid stimulates gluconeogenesis via Ca2+/PLC, cPLA2, and PPAR pathways through GPR40 in primary cultured chicken hepatocytes. , 2008, American journal of physiology. Cell physiology.

[18]  H. Edlund,et al.  Gpr40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion , 2008, Diabetes.

[19]  J. Fornwald,et al.  Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules , 2006, British journal of pharmacology.

[20]  D. Drucker.  The biology of incretin hormones. , 2006, Cell metabolism.

[21]  K. Fujiwara,et al.  Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. , 2005, American journal of physiology. Endocrinology and metabolism.

[22]  G. Tsujimoto,et al.  Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. , 2005, Biochemical and biophysical research communications.

[23]  J. Holst,et al.  Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY , 2005, European journal of gastroenterology & hepatology.

[24]  K. Wakai,et al.  Dietary Risk Factors for Inflammatory Bowel Disease: A Multicenter Case‐Control Study in Japan , 2005, Inflammatory bowel diseases.

[25]  K. Kuenzler,et al.  Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease. , 2004, Journal of pediatric surgery.

[26]  M. Parmentier,et al.  Functional Characterization of Human Receptors for Short Chain Fatty Acids and Their Role in Polymorphonuclear Cell Activation* , 2003, Journal of Biological Chemistry.

[27]  P. Brubaker,et al.  Glucagon-Like Peptide-2 and Common Therapeutics in a Murine Model of Ulcerative Colitis , 2003, Journal of Pharmacology and Experimental Therapeutics.

[28]  B. Olde,et al.  Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. , 2003, Biochemical and biophysical research communications.

[29]  S. Dowell,et al.  The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids* , 2003, The Journal of Biological Chemistry.

[30]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[31]  J. Palazzo,et al.  Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. , 2000, Journal of pediatric surgery.

[32]  U. Gether.  Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.

[33]  B. Yusta,et al.  Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. , 1999, The American journal of physiology.

[34]  A Ulloa-Aguirre,et al.  Structure-activity relationships of G protein-coupled receptors. , 1999, Archives of medical research.

[35]  D. Drucker.  Glucagon-like Peptide 2 , 1999, Trends in Endocrinology & Metabolism.

[36]  S. Targan,et al.  A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. , 1997, Journal of immunology.

[37]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[38]  P. Kovanen,et al.  TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. , 1996, Journal of immunology.

[39]  N. Seidah,et al.  Role of prohormone convertases in the tissue-specific processing of proglucagon. , 1996, Molecular endocrinology.

[40]  D. Steiner,et al.  Differential Processing of Proglucagon by the Subtilisin-like Prohormone Convertases PC2 and PC3 to Generate either Glucagon or Glucagon-like Peptide (*) , 1995, The Journal of Biological Chemistry.

[41]  T. Carlos,et al.  Leukocyte-endothelial adhesion molecules. , 1994, Blood.

[42]  W. Kolch,et al.  Mechanism of inhibition of Raf-1 by protein kinase A , 1994, Molecular and cellular biology.

[43]  R. Medcalf,et al.  Transcriptional antagonism of phorbol ester-mediated induction of plasminogen activator inhibitor types 1 and 2 by cyclic adenosine 3',5'-monophosphate. , 1992, Endocrinology.

[44]  J. Gamble,et al.  Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Linoleic acid , a dietary n6 polyunsaturated fatty acid , and the aetiology of ulcerative colitis : a nested case – control study within a European prospective cohort study The IBD in EPIC Study Investigators , 2009 .

[46]  J. Holst,et al.  Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. , 2006, Gastroenterology.

[47]  J. Miyazaki,et al.  Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. , 2005, Cell and tissue research.

[48]  G. Tsujimoto,et al.  Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 , 2005, Nature Medicine.

[49]  G. Uhl,et al.  GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA. , 2004, The Biochemical journal.

[50]  B. Yusta,et al.  Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. , 1999, The American journal of physiology.

[51]  B. Yusta,et al.  Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. , 1999, American journal of physiology. Gastrointestinal and liver physiology.